A whole genome association study for determinants of clinical outcome and treatment response in chronic hepatitis C

慢性丙型肝炎感染（CHC）会导致肝功能衰竭，肝癌和死亡。治疗反应率很低。对增加个体发展严重肝病风险或导致治疗失败的因素的理解是有限的。这是第一个此类项目，将涉及筛选1600名CHC患者与疾病结果和治疗反应相关的基因，以确定药物和疫苗开发的新靶点

Chronic hepatitis C infection (CHC) causes liver failure, liver cancer and death. The treatment response rate is poor. Understanding of the factors that increase an individual’s risk of developing serious liver disease, or that lead to treatment failure, is limited. This project, the first of its kind, will involve screening 1600 CHC patients for genes that are associated with disease outcome and treatment response, to identify novel targets for drug and vaccine development